Taken together, large trials conducted specifically in CKD patients with or without T2DM provided solid evidence that the addition of an SGLT-2 inhibitor to standard-of-care treatment, including a RAS-blocker, is effective in slowing the progression of kidney injury to ESKD and in improving cardiovascular outcomes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.